

**Supplemental appendix:**

**Samples**

*Nasal swab samples from subjects with breakthrough infections (n=97)*

Samples were collected with informed consent under the auspices of Onom IRB 241 and IRB 242. We obtained nasal swabs from 97 subjects with breakthrough infections after vaccination. Fifty-two (53.6%) were females (average age: 42.8±13.8 years); 45 (48.4%) were males (average age: 41.9±15.5 years). Eighty-four (86.6%) were fully vaccinated i.e. received both (prime and booster) doses of vaccines; 13 (13.4%) received only the first (prime) dose of vaccine prior to breakthrough infection. Out of 84 who received both doses, 53 (63.1%) received Sinopharm, 28 (33.3%) received Covishield/AstraZeneca, 2 (2.4%) received Sputnik, and one (1.2%) received Pfizer/BioNTech.

Vaccine name	Sex (M/F) (subject numbers) (n=97)	Age in years (average ± S.D.)	Two doses vaccinee (n=) vs single dose vaccinee (n=)	Interval between second vaccine dose and infection (average days ± S.D.)	Interval between only vaccine dose and infection (average days ± S.D.)	Total SARS-CoV-2 complete genome sequence recovered (n=92)	No. of Alpha variant (n=87)	No. of Delta variant (n=5)
Sinopharm	M (27)	47.07±15.86	25 vs 2	40.32±20.6	43.50±11.3			
	F (30)	45.8 ±13.53	28 vs 2	45.58±21.5	43.00±16.0			
	Total (57)	46.4 ±14.69	53 vs 2	43.06±20.6	43.25±11.3	55	54	1
Covishield	M (13)	32.3 ±10.92	13 vs 0	66.85±5.2	NA			
	F (15)	39.67±12.64	15 vs 0	68.38±5.2	NA			
	Total (28)	36.25±12.43	28 vs 0	67.79±53.5	NA	26	23	3
Sputnik V	M (4)	36.75±10.54	0 vs 4	NA	50.75±20.2			
	F (4)	41.75±10.73	2 vs 2	87.00±7.00	36.5±0.5			
	Total (8)	39.25±10.92	2 vs 6	87.00±7.00	46±17.8	7	7	0
Pfizer BioNTech	M (1)	49.00	1 vs 0	7.00±0	NA			
	F (3)	29.3±1.24	0 vs 3	NA	25.73±19.7			
	Total (4)	34.25±8.58	1 vs 3	7.00±0	25.33±19.7	4	3	1

Supplemental table 1- Demographic information of Covid-19 patients with breakthrough infections

*Plasma samples from healthy vaccinated individuals (n=100)*

Samples were collected with informed consent under the auspices of Onom IRB 241 and IRB 242. Of 100 subjects, 24 (24%) received two doses of Sinopharm, 24 (24%) received two doses of Covishield/AZN, 24 (24%) received two doses of Sputnik, 24 (24%) two doses of Pfizer/BioNTech (prime and booster); 4 (4%) received two doses of Sinopharm and one dose of Pfizer/BioNTech. All samples were tested for anti-spike SARS-CoV-2 antibodies, and anti-nucleocapsid-phosphoprotein SARS-CoV-2 antibodies using

24 EUROIMMUN ELISA kits, and for neutralizing antibodies using an end-point viral  
25 neutralization assay [1].


26

## 27 SARS-CoV-2 Sequencing

28 RNA extracted using QIAcube HT (Qiagen) was employed for SARS-CoV-2 complete  
29 genomic sequencing. Illumina libraries were prepared and enriched for SARS-CoV-2  
30 sequences using Mybaits capture system (Arbor Biosciences) [2]. Captured libraries were  
31 pooled and sequenced on the Illumina Nextseq 2000; and ~6-8 million reads/samples  
32 were generated. After demultiplexing, reads were mapped and aligned against the SARS-  
33 CoV-2 reference sequence (accession no. NC\_045512).

34

35



36

37

38 **Supplemental Figure 1.** A] Scatter plot showing EUROIMMUN Anti-SARS-CoV-2 IgG ELISA readings  
39 optical density (O.D.); B] Scatter plot showing EUROIMMUN Anti-SARS-CoV-2 NCP IgG ELISA readings  
40 (O.D.). Negative < 0.8 O.D.; Weak positive 0.8-1.1 O.D.; Positive >1.1 O.D.

41

42

- 43 1. Eckhardt CM, Cummings MJ, Rajagopalan KN, et al. Evaluating the efficacy and safety of  
44 human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A  
45 structured summary of a study protocol for a randomized controlled trial. *Trials*  
46 2020;**21**(1):499 doi: 10.1186/s13063-020-04422-y[published Online First: Epub Date] | .  
47 2. Tillett RL, Sevinsky JR, Hartley PD, et al. Genomic evidence for reinfection with SARS-CoV-2: a  
48 case study. *Lancet Infect Dis* 2021;**21**(1):52-58 doi: 10.1016/S1473-3099(20)30764-  
49 7[published Online First: Epub Date] | .  
50